Baricitinib in Alopecia Areata: Real-Life Changes in Lipid Profile and Hematologic Inflammation Indices at 52 Weeks

An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.

Baricitinib, approved for alopecia areata, might be considered for treating receding hairlines. The discussion is about the possibility of an over-the-counter topical version for androgenic alopecia.

The conversation is about baricitinib, a medicine that can help with hair loss, and why it isn't more popular or widely discussed. No specific experiences with the treatment were shared.

An arthritis drug restored significant hair in people with alopecia areata, but it is not effective for male pattern baldness. The drug, Upadacitinib, has serious side effects and is expensive.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.